Back
Back
Back

Annual Conference & Webinar Schedule

Please join Acella Pharmaceuticals for the following conferences and register to attend one of our product theaters highlighting NP Thyroid®.

March

California Association of Nurse Practitioners
(CANP)

March 19-21 – Anaheim, CA

Booth #: 424

Product Theater

Wednesday, March 20 at 1:15-2:30 pm PT
with Speaker Mandy Cotten, APRN, FNP-C

Title

When Hypothyroid Patients Speak, Are We Listening?

May

American Academy of Anti-Aging Medicine
(A4M)

May 3-5 – West Palm Beach, FL

Booth #: TBD

Webinar

May 7 – Virtual Event

Join us on your lunch hour.

Tuesday, May 7 at 12:15 pm ET, 1:15 pm ET or 3:15 pm ET
with Speakers Angela Mazza, DO, ABAARM, FAAMFM, ECNU, CDE, and David Robertson, MD

Title

Answering Your Questions on Desiccated Thyroid Extract (DTE)

Nurse Practitioner Associates for Continuing Education
(NPACE)

May 14-16 – Clearwater, FL

American Academy of Physician Associates
(AAPA)

May 18-22 – Houston, TX

Booth #: 1628

June

Endocrine Society

June 1-4 – Boston, MA

Booth #: 728

Product Theater

Saturday, June 1 at 12:30-1:30 pm ET
with Speakers Elizabeth A. McAninch, MD and Thanh D. Hoang, DO, FACP, FACE

Title

Two Researchers' Perspectives on the Changing Landscape of Hypothyroidism Treatment

American Association of Nurse Practitioners
(AANP)

June 25-30 – Nashville, TN

Booth #: 1331

Product Theater

Wednesday, June 26 at 12:00-1:15 pm CT
with Speakers Barbara Dehn, RN, MS, NP, FAANP, NCMP & Laura Casey DNP, APRN, FNP-C

Title

Lessons in Hypothyroidism: A practical course on desiccated thyroid extract (DTE) as a treatment option

July

National Nurse Practitioner Symposium
(NNPS)

July 17-21 – Keystone, CO

Booth #: 201

Product Theater

Thursday, July 18 at 11:30 am-1:00 pm MT
with Speaker Christine Kessler, MN, ANP-BC, CNS, BC-ADM, FAANP

Title

Managing the Unique Needs of Patients Living With Hypothyroidism

August

Florida Nurse Practitioner Network
(FNP)

August 22-24 – Orlando, FL

Booth #: TBD

Product Theater

Friday, August 24 at 12:00-1:00 pm ET
with Speaker Mandy Cotten, APRN, FNP-C

Title

Coming Soon!

Western Endocrine Association
(WEA)

Aug 25-27 – Sedona, AZ

Booth #: TBD

September

Texas Nurse Practitioners
(TNP)

September 5-8 – Round Rock, TX

Booth #: 207

Product Theater

Saturday, September 7 at 8:00-9:00 am CT
with Speaker Christine Kessler MN, ANP-BC, CNS, BC-ADM, FAANP

Title

TBD

North American Menopause Society
(NAMS)

September 10-14 – Chicago, IL

Booth #: TBD

Nurse Practitioners in Women's Health
(NPWH)

September 25-28 – Chicago, IL

Booth #: TBD

October

Nurse Practitioner Associates for Continuing Education
(NPACE)

October 8-10 – Cape Cod, MA

American Thyroid Association
(ATA)

October 30 - November 3 – Chicago, IL

Booth #: TBD

Product Theater

Thursday, October 31 at 12:40-1:40 pm CT

Title

Coming Soon

November

Nurse Practitioner Associates for Continuing Education
(NPACE)

November 4-7 – Dana Point, CA

December

American Academy of Anti-Aging Medicine
(A4M)

December 13-15 – Las Vegas, NV

Booth #: TBD

Note that DTE products, including NP Thyroid®, have not been reviewed by the FDA for safety or efficacy.

INDICATIONS AND IMPORTANT RISK INFORMATION, INCLUDING BOXED WARNING
Important Risk Information

Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
  • NP Thyroid® is contraindicated in patients with uncorrected adrenal insufficiency, untreated thyrotoxicosis, and hypersensitivity to any component of the product.
  • In the elderly and in patients with cardiovascular disease, NP Thyroid® should be used with greater caution than younger patients or those without cardiovascular disease.
  • Use of NP Thyroid® in patients with diabetes mellitus or adrenal cortical insufficiency may worsen the intensity of their symptoms.
  • The therapy of myxedema coma requires simultaneous administration of glucocorticoids.
  • Concomitant use of NP Thyroid® with oral anticoagulants alters the sensitivity of oral anticoagulants. Prothrombin time should be closely monitored in thyroid-treated patients on oral anticoagulants.
  • In infants, excessive doses of NP Thyroid® may produce craniosynostosis.
  • Partial loss of hair may be experienced by children in the first few months of therapy but is usually transient.
  • Adverse reactions associated with NP Thyroid® therapy are primarily those of hyperthyroidism due to therapeutic overdosage.
  • Many drugs and some laboratory tests may alter the therapeutic response to NP Thyroid®. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. Administer at least 4 hours before or after drugs that are known to interfere with absorption. Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption.
  • NP Thyroid® should not be discontinued during pregnancy, and hypothyroidism diagnosed during pregnancy should be promptly treated.

Indication

NP Thyroid® (thyroid tablets, USP) is a prescription medicine that is used to treat a condition called hypothyroidism from any cause, except for cases of temporary hypothyroidism, which is usually associated with an inflammation of the thyroid (thyroiditis). It is meant to replace or supplement a hormone that is usually made by your thyroid gland.

NP Thyroid® is also used in the treatment and prevention of normal functioning thyroid goiters, such as thyroid nodules, Hashimoto’s thyroiditis, multinodular goiter, and in the management of thyroid cancer.

Revised 10/2023